What are the key laboratory findings for Polymyalgia Rheumatica (PMR)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Laboratory Findings for Polymyalgia Rheumatica

The key laboratory findings in PMR include elevated inflammatory markers (ESR and/or CRP in >90% of cases), with ESR >40 mm/hr being particularly significant for predicting relapse risk, though normal inflammatory markers do not exclude the diagnosis. 1, 2

Core Laboratory Panel

Essential inflammatory markers:

  • ESR is elevated (>40 mm/1st hour) in approximately 91.5% of patients and is the preferred marker for long-term monitoring and predicting relapse risk 2, 3
  • CRP is elevated in 98.9% of patients at diagnosis and may be more sensitive than ESR 3
  • Both ESR and CRP should be measured as part of the basic laboratory dataset 1

Baseline laboratory tests to exclude mimicking conditions:

  • Rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA) to exclude rheumatoid arthritis 1, 4
  • Complete blood count to assess for anemia and other causes of inflammation 1
  • Glucose, creatinine, and liver function tests to establish baseline before glucocorticoid therapy 1
  • Bone profile (calcium, alkaline phosphatase) to assess bone health before steroid initiation 1
  • Urinalysis to exclude other inflammatory or infectious conditions 1

Additional Recommended Tests

Secondary screening tests:

  • Protein electrophoresis to exclude paraproteinemia 1
  • Thyroid stimulating hormone (TSH) to rule out thyroid disorders 1
  • Creatine kinase to exclude myopathies and myositis 1
  • Vitamin D level before glucocorticoid therapy 1

Special Considerations for Normal Inflammatory Markers

PMR with normal ESR/CRP occurs in 7-22% of cases and has distinct characteristics:

  • Younger age at diagnosis 5, 6
  • Longer symptom duration before diagnosis 7, 5
  • Lower frequency of constitutional symptoms (fever, weight loss) 6
  • Lower comorbidity rates 5

When ESR and CRP are normal but clinical suspicion is high:

  • Measure serum amyloid A (SAA), which may be elevated when ESR and CRP are normal 5
  • Consider ultrasonography to demonstrate bursitis 5
  • Normal inflammatory markers warrant specialist referral according to EULAR/ACR guidelines 2

Prognostic Laboratory Markers

High ESR (>40 mm/hr) at diagnosis is associated with:

  • Higher relapse rates requiring prolonged therapy 8, 2
  • May guide decision for higher initial glucocorticoid doses 2

Persistently elevated inflammatory markers during treatment:

  • Persistently elevated CRP and IL-6 during the first year of therapy predict higher risk of relapse/recurrence 3
  • IL-6 levels remain elevated in 37.2% of patients after 4 weeks of prednisone therapy 3
  • Patients with persistently elevated IL-6 during the first year have the highest relative risk of relapse 3

Common Pitfalls

Do not exclude PMR based solely on normal ESR or CRP - approximately 14% of patients have normal values at diagnosis, and clinical response to low-dose glucocorticoids (12.5-25 mg prednisone) plus a drop in inflammatory markers after therapy can confirm the diagnosis 7, 5, 6

References

Guideline

Diagnostic Approach for Polymyalgia Rheumatica

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

ESR as a Preferred Marker for Polymyalgia Rheumatica

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Polymyalgia Rheumatica Diagnosis and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Polymyalgia rheumatica with a low erythrocyte sedimentation rate: comparison of 10 cases with 10 cases with high erythrocyte sedimentation rate.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 1997

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.